ClinicalTrials.gg
CompletedNCT03712228Updated Nov 8, 2022Results posted

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

A Phase 2 interventional study of Factor XIIa antagonist monoclonal antibody and Placebo in Hereditary Angioedema, sponsored by CSL Behring. Completed at 16 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Angioedemas, Hereditary by CSL Limited — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · CSL Limited.

Started
2018
the only one that year
Phase 2
Only one
of the 11
Registered
5th of 11
by date

Among the 11 studies in Angioedemas, Hereditary by CSL Limited, this one is the only one that started in 2018, is the only one in phase 2, and was the 5th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 11 studies in Angioedemas, Hereditary by CSL Limited is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Angioedemas, Hereditary by CSL Limited, or all of them as a file.
02

Study summary

This is a multicenter, randomized, placebo-controlled, parallel-arm, phase 2 study to investigate the clinical efficacy, pharmacokinetics, and safety of CSL312 as prophylaxis to prevent attacks in subjects with HAE.

03

Conditions studied

  • Hereditary Angioedema
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Aged ≥ 18 to ≤ 65 years
  • A diagnosis of C1-INH HAE or FXII/PLG HAE;
  • For subjects with C1-INH HAE: ≥ 4 HAE attacks over a consecutive 2-month period during the 3 months before Screening, as documented in the subject's medical record.

Exclusion criteria

Exclusion Criteria:

  • History of arterial or venous thrombosis, or current clinically significant prothrombotic risk
  • History of an uncontrolled, abnormal bleeding event due to a coagulopathy, or a current clinically significant coagulopathy or clinically significant risks for bleeding events
  • Known incurable
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects with C1-INH HAE receiving buffer only

    Drug: Placebo

  • Active comparator
    CSL312 (low)

    Subjects with C1-INH HAE receiving low dose CSL312

    Biological: Factor XIIa antagonist monoclonal antibody

  • Active comparator
    CSL312 (med)

    Subjects with C1-INH HAE receiving medium dose CSL312

    Biological: Factor XIIa antagonist monoclonal antibody

  • Active comparator
    CSL312 (high)

    Subjects with C1-INH HAE receiving high dose CSL312

    Biological: Factor XIIa antagonist monoclonal antibody

  • Active comparator
    CSL312 (med/high)

    Subjects with C1-INH HAE receiving medium/high dose CSL312

    Biological: Factor XIIa antagonist monoclonal antibody

Interventions

06

What researchers measure

Primary outcomes

  1. The Mean Time Normalized Number of HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1

    The time-normalized number of HAE attacks per month during Treatment Period 1 for a subject was calculated as the (number of HAE attacks / length of subject's evaluation period in days) \* 30.4375

    Time frame: 13 weeks

Secondary outcomes

  1. The Number of Responder Subjects With C1-INH HAE During Treatment Period 1

    Response is defined as a ≥ 50% relative reduction in the time-normalized number of HAE attacks (per month) during Treatment Period 1 compared to each subject's time-normalized number of HAE attacks (per month) during the Run-in Period

    Time frame: 13 weeks

  2. The Percentage of Responder Subjects With C1-INH HAE During Treatment Period 1

    Response is defined as a ≥ 50% relative reduction in the time-normalized number of HAE attacks (per month) during Treatment Period 1 compared to each subject's time-normalized number of HAE attacks (per month) during the Run-in Period.

    Time frame: 13 weeks

  3. The Number of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  4. The Percentage of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  5. The Number of Mild, Moderate or Severe HAE Attacks in Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  6. The Percentage of Mild, Moderate or Severe HAE Attacks in Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  7. The Mean Time-normalized Number of Mild, Moderate or Severe HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1

    The time-normalized number of HAE attacks per month during Treatment Period 1 for a subject was calculated as the (number of HAE attacks / length of subject's evaluation period in days) \* 30.4375

    Time frame: 13 weeks

  8. The Number of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  9. The Percentage of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  10. Maximum Concentration (Cmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  11. Area Under the Concentration-time Curve in 1 Dosing Interval (AUC0-tau) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  12. Time of Maximum Concentration (Tmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  13. Terminal Elimination Half-life (T1/2) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  14. Clearance (CL/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  15. Volume of Distribution During the Elimination Phase (Vz/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1

    Time frame: 13 weeks

  16. The Number of Subjects With C1-INH HAE With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), Injection Site Reactions (ISRs), Binding Antibodies to CSL312 During Treatment Period 1

    Adverse events of special interest is defined as anaphylaxis, thromboembolic events, and bleeding events.

    Time frame: 13 weeks

07

Results

Posted Nov 8, 2022

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestonePlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)CSL312 (FXII/PLG HAE)
Started898766
Completed898765
Not completed000001
Withdrew: Lack of efficacy000001
Treatment Period 2
Participant flow — Treatment Period 2
MilestonePlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)CSL312 (FXII/PLG HAE)
Started00201802
Completed00201602
Not completed000200
Withdrew: Pregnancy000100
Withdrew: Withdrawal by subject000100

Outcome measures

PrimaryThe Mean Time Normalized Number of HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1

The time-normalized number of HAE attacks per month during Treatment Period 1 for a subject was calculated as the (number of HAE attacks / length of subject's evaluation period in days) \* 30.4375

Time frame:
13 weeks
Reported as:
Mean · Number of HAE attacks per month
The Mean Time Normalized Number of HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1
Number of HAE attacks per monthPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
The Mean Time Normalized Number of HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 14.24 ± 1.8010.48 ± 1.0570.05 ± 0.1270.35 ± 0.4070.14 ± 0.222
SecondaryThe Number of Responder Subjects With C1-INH HAE During Treatment Period 1

Response is defined as a ≥ 50% relative reduction in the time-normalized number of HAE attacks (per month) during Treatment Period 1 compared to each subject's time-normalized number of HAE attacks (per month) during the Run-in Period

Time frame:
13 weeks
Reported as:
Number · Number of participants
The Number of Responder Subjects With C1-INH HAE During Treatment Period 1
Number of participantsPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
The Number of Responder Subjects With C1-INH HAE During Treatment Period 109866
SecondaryThe Percentage of Responder Subjects With C1-INH HAE During Treatment Period 1

Response is defined as a ≥ 50% relative reduction in the time-normalized number of HAE attacks (per month) during Treatment Period 1 compared to each subject's time-normalized number of HAE attacks (per month) during the Run-in Period.

Time frame:
13 weeks
Reported as:
Number · percentage of participants
The Percentage of Responder Subjects With C1-INH HAE During Treatment Period 1
percentage of participantsPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
The Percentage of Responder Subjects With C1-INH HAE During Treatment Period 10100.0100.085.7100.0
SecondaryThe Number of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Number · Number of participants
The Number of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1
Number of participantsPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
The Number of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 105734
SecondaryThe Percentage of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Number · percentage of participants
The Percentage of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1
percentage of participantsPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
The Percentage of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1055.687.542.966.7
SecondaryThe Number of Mild, Moderate or Severe HAE Attacks in Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Number · Number of HAE attacks
The Number of Mild, Moderate or Severe HAE Attacks in Subjects With C1-INH HAE During Treatment Period 1
Number of HAE attacksPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
Mild323022
Moderate439140
Severe200010
SecondaryThe Percentage of Mild, Moderate or Severe HAE Attacks in Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Number · percentage of HAE attacks
The Percentage of Mild, Moderate or Severe HAE Attacks in Subjects With C1-INH HAE During Treatment Period 1
percentage of HAE attacksPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
Mild33.725.0028.6100.0
Moderate45.375.0100.057.10
Severe21.10014.30
SecondaryThe Mean Time-normalized Number of Mild, Moderate or Severe HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1

The time-normalized number of HAE attacks per month during Treatment Period 1 for a subject was calculated as the (number of HAE attacks / length of subject's evaluation period in days) \* 30.4375

Time frame:
13 weeks
Reported as:
Mean · Number of HAE attacks per month
The Mean Time-normalized Number of Mild, Moderate or Severe HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1
Number of HAE attacks per monthPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
Mild1.42 ± 1.3950.12 ± 0.1770.0 ± 0.0000.10 ± 0.1680.14 ± 0.222
Moderate1.93 ± 1.4030.36 ± 1.0870.05 ± 0.1270.20 ± 0.3470.0 ± 0.000
Severe0.89 ± 1.3650.0 ± 0.0000.0 ± 0.0000.05 ± 0.1360.0 ± 0.000
SecondaryThe Number of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Number · Number of participants
The Number of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1
Number of participantsPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
The Number of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 183120
SecondaryThe Percentage of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Number · percentage of participants
The Percentage of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1
percentage of participantsPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
The Percentage of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1100.033.312.528.60
SecondaryMaximum Concentration (Cmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Mean · ug/mL
Maximum Concentration (Cmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
ug/mLPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
Maximum Concentration (Cmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1—10.6 ± 6.0915.9 ± 5.2256.4 ± 15.9—
SecondaryArea Under the Concentration-time Curve in 1 Dosing Interval (AUC0-tau) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Mean · h*μg/mL
Area Under the Concentration-time Curve in 1 Dosing Interval (AUC0-tau) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
h*μg/mLPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
Area Under the Concentration-time Curve in 1 Dosing Interval (AUC0-tau) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1—4507 ± 24247166 ± 241026514 ± 8151—
SecondaryTime of Maximum Concentration (Tmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Median · hours
Time of Maximum Concentration (Tmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
hoursPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
Time of Maximum Concentration (Tmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1—143.38 (45.4 to 196)165.51 (116 to 218)165.63 (72.4 to 188)—
SecondaryTerminal Elimination Half-life (T1/2) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Mean · hours
Terminal Elimination Half-life (T1/2) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
hoursPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
Terminal Elimination Half-life (T1/2) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1—411.7 ± 96.97394.0 ± 85.64443.5 ± 44.00—
SecondaryClearance (CL/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Mean · L/hour
Clearance (CL/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
L/hourPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
Clearance (CL/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1—0.0198 ± 0.00790.0303 ± 0.00840.0246 ± 0.0079—
SecondaryVolume of Distribution During the Elimination Phase (Vz/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame:
13 weeks
Reported as:
Mean · Liters
Volume of Distribution During the Elimination Phase (Vz/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
LitersPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
Volume of Distribution During the Elimination Phase (Vz/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1—10.6 ± 5.1017.0 ± 4.7817.1 ± 6.67—
SecondaryThe Number of Subjects With C1-INH HAE With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), Injection Site Reactions (ISRs), Binding Antibodies to CSL312 During Treatment Period 1

Adverse events of special interest is defined as anaphylaxis, thromboembolic events, and bleeding events.

Time frame:
13 weeks
Reported as:
Number · Number of participants
The Number of Subjects With C1-INH HAE With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), Injection Site Reactions (ISRs), Binding Antibodies to CSL312 During Treatment Period 1
Number of participantsPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)
AEs77774
SAEs00000
AESI10000
ISRs21142
Binding Antibodies to CSL31210000

Adverse events

Collected over Approximately 129 weeks per participant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/8 (0%)0/8 (0%)7/8 (87.5%)
CSL312 (Low)0/9 (0%)0/9 (0%)7/9 (77.8%)
CSL312 (Med)0/8 (0%)0/8 (0%)7/8 (87.5%)
CSL312 (High)0/7 (0%)0/7 (0%)7/7 (100%)
CSL312 (Med/High)0/6 (0%)0/6 (0%)4/6 (66.7%)
CSL312 (Med-Period 2)0/36 (0%)1/36 (2.8%)25/36 (69.4%)
CSL312 (Med/High-Period 2)0/3 (0%)0/3 (0%)2/3 (66.7%)
CSL312 (High-Period 2)0/18 (0%)1/18 (5.6%)17/18 (94.4%)
CSL312 (FXII/PLG HAE-Period 1)0/6 (0%)1/6 (16.7%)1/6 (16.7%)
CSL312 (FXII/PLG HAE-Period 2)0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)CSL312 (Med-Period 2)CSL312 (Med/High-Period 2)CSL312 (High-Period 2)CSL312 (FXII/PLG HAE-Period 1)CSL312 (FXII/PLG HAE-Period 2)
Hereditary angioedemaCongenital, familial and genetic disorders0/80/90/80/70/60/360/30/181/60/2
AsthmaRespiratory, thoracic and mediastinal disorders0/80/90/80/70/60/360/31/180/60/2
Diverticular perforationGastrointestinal disorders0/80/90/80/70/61/360/30/180/60/2
Most frequent other events
Showing 10 of 102
Most frequent other events
EventPlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)CSL312 (Med-Period 2)CSL312 (Med/High-Period 2)CSL312 (High-Period 2)CSL312 (FXII/PLG HAE-Period 1)CSL312 (FXII/PLG HAE-Period 2)
COVID-19Infections and infestations0/80/90/80/70/60/360/30/180/62/2
Urinary tract infectionInfections and infestations1/80/90/80/70/62/360/31/180/61/2
PyrexiaGeneral disorders0/80/91/81/70/60/360/31/180/61/2
DyspepsiaGastrointestinal disorders0/80/90/80/70/62/360/30/180/61/2
HeadacheNervous system disorders1/80/91/82/72/66/360/34/180/61/2
DizzinessNervous system disorders0/80/90/81/70/60/360/31/180/61/2
MyalgiaMusculoskeletal and connective tissue disorders1/80/90/80/70/60/360/31/180/61/2
Herpes zosterInfections and infestations0/80/90/80/70/60/360/30/180/61/2
InfluenzaInfections and infestations0/80/90/80/70/60/360/30/180/61/2
MalaiseGeneral disorders0/80/90/80/70/60/360/30/180/61/2

Baseline characteristics

The Intent-to-Treat (ITT) population consisted of all subjects who provided informed consent, underwent any study screening procedure, and who were assigned to treatment in Treatment Period 1 or to treatment in Treatment Period 2, regardless of whether they received investigational product.

Age, Categorical
Age, Categorical(Participants)PlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)CSL312 (FXII/PLG HAE)Total
<=18 years0000000
Between 18 and 65 years89866643
>=65 years0001001
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)CSL312 (FXII/PLG HAE)Total
Female47253627
Male42623017
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)CSL312 (FXII/PLG HAE)Total
Hispanic or Latino1000102
Not Hispanic or Latino79875642
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)CSL312 (FXII/PLG HAE)Total
American Indian or Alaska Native0000000
Asian0002103
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000101
White79854639
More than one race1000001
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)PlaceboCSL312 (Low)CSL312 (Med)CSL312 (High)CSL312 (Med/High)CSL312 (FXII/PLG HAE)Total
Canada1321007
United States42022111
Israel0221229
Germany32432317
08

Study locations

16 sites
  • Donald S. Levy
    Orange, California 92868, United States
  • Allergy & Asthma Clinical Research
    Walnut Creek, California 94598, United States
  • Immunoe Health Centers
    Centennial, Colorado 80112, United States
  • Institute for Asthma and Allergy
    Chevy Chase, Maryland 20815, United States
  • The Mount Sinai Hospital
    New York, New York 10029, United States
  • Pennsylvania State University
    Hershey, Pennsylvania 17033, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Campbelltown Hospital
    Campbelltown, New South Wales 2560, Australia
  • University of Alberta
    Edmonton, Alberta T6G 2B7, Canada
  • Allergy and Clinical Immunology McMaster University
    Hamilton, Ontario L8S 4K1, Canada
  • Ottawa Allergy Research Corp
    Ottawa, Ontario K1G 6C6, Canada
  • Charité Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Universitätsklinikum Frankfurt Goethe-Universität
    Frankfurt, 60590, Germany
  • Hautklinik und Poliklinik der Universitätsklinik Mainz
    Mainz, 55131, Germany
  • HZRM Hämophilie Zentrum Rhein Main GmbH
    Mörfelden-Walldorf, 64546, Germany
  • Barzilai University Medical Center
    Ashkelon, 7830604, Israel
09

References and documents

Publications

  • Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. PubMed 36326435 ↗
  • Craig T, Magerl M, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, Yang WH, Ritchie B, Aygoren-Pursun E, Keith PK, Busse P, Feuersenger H, Pawaskar D, Jacobs I, Pragst I, Doyle MK. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2022 Mar 5;399(10328):945-955. doi: 10.1016/S0140-6736(21)02225-X. Epub 2022 Feb 24. PubMed 35219377 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Oct 2021, 35 months.

Results were first posted in Nov 2022, 1 year after primary completion.

Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2018
First posted
Oct 19, 2018
StartActual
Oct 29, 2018
Primary completionActual
Oct 15, 2021
CompletionActual
Oct 15, 2021
Results first posted
Nov 8, 2022
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03712228
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Oct 19, 2018
Start date
Oct 29, 2018
Primary completion
Oct 15, 2021
Completion
Oct 15, 2021
Results posted
Nov 8, 2022
Last update
Nov 8, 2022

Study contacts

Study Director
study director · CSL Behring LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garadacimab

Start the discussion